Found 387 Neoplasms trials
A listing of Neoplasms medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Pragmatic Phase Iii Randomized Trial of Proton vs. Photon Therapy for Patients with Non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (RADCOMP) Consortium Trial
This is a pragmatic randomized clinical trial in which patients with locally advanced breast cancer will be randomized to either proton or photon therapy and followed longitudinally for cardiovascular morbidity and mortality, health-related quality of life (HRQOL), and cancer control outcomes. We hypothesize that proton therapy, as part of multi-modality …
UPCC 09517: Phase II study of Pembrolizumab and Itacitinib (INCB039110) for First Line Treatment of Metastatic Non-Small Cell Lung Cancer Expressing PD-L1
The main purpose of this study is to examine the efficacy of adding itacitinib (also known as INCB039110) to pembrolizumab in patients with previously untreated metastatic non-small cell lung cancer.
A Phase II randomized double-blind study of the use of Rucaparib vs. placebo maintenance therapy in metastatic and recurrent endometrial cancer
This study plans to learn more about the use of Rucaparib maintenance therapy after completion of prior therapy for recurrent endometrial cancer. Rucaparib belongs to a drug class called PARP inhibitors. There are currently three drugs approved by the U.S. Food and Drug Administration (FDA) in the setting of ovarian …
Investigating Potential of Personalized Biomarkers in Redefining Treatment Response in Patients with Glioblastoma using Multiparametric MRI and Liquid Biopsy
This study aims to investigate 30 patients with a diagnosis of Glioblastoma to develop a decision support system by incorporating advanced MR imaging, liquid biopsy, and MGMT promoter status to determine with higher accuracy whether tumor changes are true progression or pseudo progression. Analysis of these results will hopefully have …
Trial of ASP-1929 Photoimmunotherapy Versus Physician's Choice Standard of Care for the Treatment of Locoregional Recurrent Head and Neck Squamous Cell Carcinoma
This is a Phase 3, randomized, double-arm, open-label trial of ASP-1929 photoimmunotherapy (ASP-1929 PIT) versus physician's choice standard of care (SOC) for the treatment of locoregional, recurrent head and neck squamous cell carcinoma (HNSCC) in patients who have failed or progressed on or after at least two lines of therapy, …
UPCC 16520: A Phase Ib-II Trial of Tocilizumab and Atezolizumab in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy
This is an investigator-initiated, open label phase Ib study examining 2nd line atezolizumab and tocilizumab in a cohort of recurrent/metastatic non-small cell lung cancer patients who have received prior immune checkpoint inhibitor therapy with or without other forms of therapy (i.e. chemotherapy, radiation). Patients with driver mutations in EGFR, ALK, …
A Study to Investigate the Safety and Efficacy of OTL38 Injection for Intraoperative Imaging of Folate Receptor Positive Lung Nodules
A study for persons with suspected lung cancer patients scheduled to undergo endoscopic or thoracic surgery per CT/PET/MRI or other imaging based on standard of care. This study aims to assess the efficacy of OTL38 and Near Infrared Imaging (NIR) at identifying pulmonary nodules within the operating theater, and to …
Study of Durvalumab (MEDI4736) Alone or in Combination With Novel Agents in Subjects With Locally Advanced, Unresectable (Stage III) Non-small Cell Lung Cancer (COAST)
The main purpose of this study is to measure when the effectiveness of durvalumab in combination with other experimental drugs is superior to the effectiveness of durvalumab when used alone. The study is also being done to evaluate the safety and tolerability of durvalumab when used alone and in combination …
Randomized Blinded Discontinuation Trial of Ocrelizumab in Early Relapsing Multiple Sclerosis
The primary study objective is to evaluate the rate of durable remission of relapsing disease activity, assessed serially both clinically and by MRI, from randomization through 48 months in participants with early relapsing multiple sclerosis who discontinue OCR after 12 and 24 months of treatment. Secondary objectives include: - Mechanistic: …
Please choose between Voice or SMS based delivery of verification code
or